We have a growing portfolio of antibody candidates in both human and animal health at various stages of development. Collaborating with strategic partners, academic institutions and industry leaders is key to delivering on our mission of bringing new medicines to patients. Existing opportunities include our Covid-19 therapeutic and African Swine Fever biologic.
We are also establishing high purity non-specific, or natural IgY, as a high-quality, effective ingredient for use in consumer health products such as nutraceuticals.
We welcome qualified private investment, strategic partnerships, and out-licensing opportunities that are consistent with this strategy.
Please contact us if you are interested in learning more.